Home › Trial NCT03970252
Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer
- Trial IDNCT03970252
- StatusCompleted
- PhaseEarly Phase 1
- Study typeInterventional
- SponsorJonsson Comprehensive Cancer Center
- Enrollment28
- Start date2019-07-24
- ConditionsBorderline Resectable Pancreatic Adenocarcinoma · Resectable Pancreatic Ductal Adenocarcinoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.